Mode
Text Size
Log in / Sign up
Phase 2 N=550 Randomized Double-blind Treatment

Topical Delivery of Vitamin D3 as Vitamin D Supplementation

Vitamin D Deficiency

Enrolled (actual)
550
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: Level of Serum 25 OHD Level Pre-treatment and Post Treatment — 12.03; 10.36; 37.17; 10.51 ng/mL — p=0.9

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Application of topical vitamin d3 (Top-D) (Drug); Application of Aloe vera gel (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Imam Abdulrahman Bin Faisal University
Primary completion
Dec 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Level of Serum 25 OHD Level Pre-treatment and Post Treatment
12.03; 10.36; 37.17; 10.51 0.9

Summary

After obtaining the approval from the IRB of University of Dammam and informed consent from 550 healthy patients, with vitamin D deficiency and vitamin D insufficiency and deficiency were recruited. Age, weight and height will be taken, a detailed history, meticulous clinical examination was performed to rule out any diseases and complete blood picture, serum calcium, phosphorous, alkaline phosphatase, Parathormone and 25 Hydroxy-vitamin D (25OHD) will be done. 25-Hydroxy Vitamin D3 was measured in house by chemiluminescence immunoassay (CLIA) and ≥30ng/mL was taken as normal, 21-29ng/mL as insufficiency and ≤20 ng/mL as deficiency. The participants were divided into two groups of 350 in study arm and 200 in control arm. All participants were instructed not to change their dietary habits and life style till the study was over. The study group of women were instructed to apply to apply Top-D (Proniosomal Delivered- Vitamin D3) 1 gram containing 5000 IU of vitamin D3. The second group used 1 gram of Aloe vera gel. The participants had no knowledge to which group they belong. A second blood sample was taken at the end of 4 months and the data was entered in the data base and analyzed using SPSS Inc version 19.

Eligibility Criteria

Inclusion Criteria

all men and women with vitamin D insufficiency and deficiency Must be able to apple the topical vitamin D3 Must be willing to sign and informed consent

Exclusion Criteria

  • Those who have normal 25OHD levels
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02735200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search